Abivax announces the release of its 2021 half-year financial report
PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF ().
*****
About Abivax ()
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.
Contacts
Abivax
Communications
Regina Jehle
63 |
Investors
LifeSci Advisors
Ligia Vela-Reid
|
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
22 |
Public Relations France
Actifin
Ghislaine Gasparetto
24 |
Public Relations France
DGM Conseil
Thomas Roborel de Climens
84 |
Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
|
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at
